Samuel F. Hunter, MD, PhD, Author at Clinical Advisor
Samuel F. Hunter, MD, PhD

Samuel F. Hunter, MD, PhD

Samuel F. Hunter, MD, PhD, is a neurologist in Franklin, Tennessee.

All articles by Samuel F. Hunter, MD, PhD

The Role of Newer Abortive Agents

In December 2019, the US Food and Drug Administration (FDA) approved the first small molecule calcitonin gene-related peptide (CGRP) antagonist for the treatment of acute migraine, ubrogepant (Ubrelvy®),1 followed closely by rimegepant (Nurtec ODT®).2 A novel serotonin (5-HT)1F receptor agonist, lasmiditan (Reyvow®), was approved in October 2019 as a new oral agent for the acute…

Next post in Neurology Information Center